

# Curriculum Vitae and Bibliography

## Evanthia Galanis, MD

### PERSONAL INFORMATION

Citizenship: -----(b)(6)-----  
Work Address: Mayo Clinic  
200 First Street SW  
Rochester, MN 55905  
507-284-3902  
email Address: galanis.evanthia@mayo.edu  
Home Address: -----(b)(6)-----

### PRESENT ACADEMIC RANK AND POSITION

**Consultant** - Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, Minnesota 2001 - Present  
**Teaching/Examining Privileges in Virology & Gene Therapy** - Mayo Graduate School 05/19/2003 - Present  
**Professor of Oncology** - College of Medicine, Mayo Clinic 02/01/2007 - Present

### EDUCATION

Greek Pasteur Institute, Greece  
Experimental part of D.Sc thesis  
Athens University School of Medicine, Athens, Greece 1990  
MD  
Athens University School of Medicine, Athens, Greece 1993  
D.Sc, "Development and application of quantitative immunoenzymatic assays (ELISAS) and immunoblotting techniques in the study of specificity and title of M1- antimitochondrial antibodies (M2-AMA).  
Yale University School of Medicine ----(b)(6)----  
Pre-graduation electives:  
Neurology, Endocrinology, Hepatology  
Mayo Graduate School of Medicine 1991 - 1994  
Residency, Internal Medicine  
Hospital Albert Schweitzer Haiti West Indies 1993  
Post-graduation elective: Tropical Medicine  
Mayo Graduate School of Medicine 1994 - 1998  
Fellowship, Hematology/Oncology

### BOARD CERTIFICATION(S)

**American Board of Internal Medicine**  
Internal Medicine 1994

**American Board of Medical Oncology**

Medical Oncology	1997
------------------	------

**European Exams in Medical Oncology**

Oncology	1997
----------	------

**Greek Boards of Medical Oncology**

Oncology	2000
----------	------

**LICENSURE**

Greece	-(b)(6)-	1990 - Present
Minnesota	-(b)(6)-	1993 - Present

**HONORS/AWARDS**

Yearly Scholarships - Greek Ministry of Education/National Scholarship Foundation	------(b)(6)-----
Valedictorian - Athens University Medical School	1990
Scholarship for Completion of D.Sc Thesis - Greek Ministry of Public Health	1990
Internal Medicine Outstanding Research Award - Mayo Graduate School of Medicine	1994
Berlex Oncology Foundation Award on Epidemiology and Clinical Trial Design	1996
Berlex Oncology Foundation Award on Genetics in Oncology	1997
Linse-Bock Fellowship in Neuro-Oncology	1997
Berlex Oncology Foundation Award on Clinical Pharmacology of Anticancer Drugs	1997
AACR Scholarship - AACR Molecular Biology Workshop	1997
AACR/Glaxo Wellcome Award - American Association for Cancer Research	1998
Outstanding Achievement Award in Oncology - Mayo Clinic	1998
Award of Excellence - 13th International Conference on Gene Therapy	2005

**PREVIOUS PROFESSIONAL POSITIONS AND MAJOR APPOINTMENTS**

<b>Instructor of Oncology</b> - College of Medicine, Mayo Clinic	01/01/1997 - 07/01/1998
<b>Assistant Professor of Oncology</b> - College of Medicine, Mayo Clinic	07/01/1998 - 10/01/2002
<b>Associate Professor of Oncology</b> - College of Medicine, Mayo Clinic	10/01/2002 - 01/31/2007

**PROFESSIONAL & COMMUNITY MEMBERSHIPS, SOCIETIES AND SERVICES**

(\*indicates office held)

**Professional Memberships & Services**

Department of Defense	
Clinical and Experimental Therapeutics #2	
*Chair	2007 - Present
Clinical and Experimental Therapeutics #4	2000 - 2005
*Review Panel Member	
Greek Ministry of Health	
Gene Therapy Committee	2000 - Present
National Institutes of Health	
National Cancer Institute	
Cancer Center Site Visit Audit Team	2003 - Present
CTEP Concept Review Committee	2005 - Present
Athens Medical Association	1990 - Present
American Medical Association	1991 - 1998
------(b)(6)-----	1993 - Present
------(b)(6)-----	1994 - Present
American College of Physicians	1995 - 1998
American Association for Cancer Research	1996 - Present
American Society of Clinical Oncology	1996 - Present
European Association for Cancer Research	1996 - Present
European Society for Medical Oncology	1996 - Present
American Society of Gene Therapy	1997 - Present
North Central Cancer Treatment Group	1998 - Present
Neuro-Oncology Committee	
*Vice Chair	2002 - Present
Novel Therapeutics Committee	1999 - Present
Society for Neuro-Oncology	1999 - Present
International Working Group for Gene Therapy	2004 - Present
<b>Journal Review &amp; Editorial Activities</b>	
Biodrugs	
Reviewer	2000 - Present
Brain	
Reviewer	2003 - Present
Breast Cancer Research and Treatment	

Reviewer	1999 - Present
British Journal of Cancer Reviewer	2000 - Present
Cancer Reviewer	1998 - Present
Cancer Detection and Prevention Reviewer	1999 - Present
Cancer Research Reviewer	2007 - Present
Clinical Cancer Research Reviewer	2001 - Present
Clinical Gastroenterology and Hepatology Reviewer	2004 - Present
Expert Opinion on Biological Therapy Reviewer	2002 - Present
Gene Therapy Editorial Board Member Reviewer	2005 - Present
Gene Therapy and Molecular Biology Editorial Board Member	
Genetic Vaccine and Therapy Editorial Board Member	
Gynecologic Oncology Reviewer	2006 - Present
Human Gene Therapy Reviewer	2000 - Present
International Journal of Cancer Reviewer	2003 - Present
Journal of Clinical Oncology Reviewer	1999 - Present
Journal of Gene Medicine Reviewer	2005 - Present
Journal of Immunotherapy Reviewer	1998 - Present
Lancet	

Reviewer	2008 - Present
Leukemia Reviewer	2006 - Present
Molecular Therapy Reviewer	2003 - Present
Tumor Targeting Reviewer	1998 - Present
Urology Reviewer	2005 - Present

## EDUCATIONAL ACTIVITIES

### Teaching

Faculty, Virology and Gene Therapy Track Mayo Graduate School	
Gene Therapy Trials in Medical Oncology Oncology Grand Rounds, Mayo Clinic Rochester, Minnesota	03/1998
Cancer Gene Therapy: Connecting Basic Research with Clinical Inquiry. Oncology Core Curriculum, Mayo Clinic	09/1998
Cancer Gene Therapy Clinical Trials at the Mayo Clinic Endocrine Research Seminar, Mayo Clinic	10/1998
Gene Therapy Clinical Trials in Medical Oncology GI Unit Scientific Meeting	04/1999
What's New in Cancer Care Cancer Connections: A Multidisciplinary Update	07/1999
Use of fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas Cytoreductive Gene Therapy, Harold W. Siebens Conference Rochester, Minnesota	09/1999
Clinical Trials in Gene Therapy for Cancer Mayo Clinic Oncology Core Curriculum Series	12/2000
Gene Therapy in the Treatment of Metastatic Renal Cell Carcinoma Renal Cell Carcinoma Symposium	12/2000
Advances in gene therapy for renal cell carcinoma Contemporary Issues in Adult Clinical Urology Department of Urology, Mayo Clinic Rochester, Minnesota	02/2001 - 03/2001
Gene therapy for prostate cancer: Recent advances Contemporary Issues in Adult Clinical Urology Department of Urology, Mayo Clinic Rochester, Minnesota	02/2001 - 03/2001
Gene Therapy in the Treatment of Brain Tumor Neurooncology Seminar - Tumor Biology Course	03/2002

## Mentorship

**INSTITUTIONAL/DEPARTMENTAL ADMINISTRATIVE RESPONSIBILITIES,  
COMMITTEE MEMBERSHIPS AND OTHER ACTIVITIES (\* indicates office held)**

Mayo Clinic Cancer Center	
Mayo Clinic Cancer Center - Rochester	
Mayo Clinic Cancer Center Committees	
Oncology Review Committee (Previously, Protocol Review Committee)	1998 - Present
Mayo Clinic SPORE in Pancreatic Cancer	
Scientific Advisory Committee	
*Member	
Mayo Foundation Committees	
Clinical Research Subcommittee	2005 - 2006

**Mayo Clinic Rochester**

## Department of Oncology

## Division of Medical Oncology

Research Committee

2000 - Present

Education Committee

2000 - 2001

Hematology/Oncology Fellowship Selection Committee

2000 - 2002

## General Clinical Research Center

\*Advisory Board Member

2004 - 2006

## Mayo Clinic Center for Translational Science Activities

\*Member

2007 - Present

Academic Affairs Committee

\*Member

2007 - Present

Research Resources Review Committee

\*Vice Chair

2007

**PRESENTATIONS****International**

Enzyme immunoassays for the determination of antibodies against mitochondrial dehydrogenase complexes in primary biliary cirrhosis  
International Congress: 25 Years of Immunoenzymatic Techniques  
Athens, Greece

09/1991

Pyruvate, a-oxo-glutarate and branched chain dehydrogenase complexes: Targets of autoantibodies in primary biliary cirrhosis  
8th International Congress of Immunology  
Budapest, Hungary

08/1992

Aneurysmal bone cysts of the spine  
2nd Congress of the European Federation of National Associations of Orthopedics and Traumatology  
Munich, Germany

07/1995

Malignant tumors of the proximal fibula  
Third Congress of the European Federation of National Associations of Orthopedics and Traumatology  
Barcelona, Spain

04/1996

Treatment of pathologic or impending pathologic fractures in multiple myeloma  
SICOT '96  
Amsterdam, Netherlands

08/1996

Ultrasound-guided immunotherapy of hepatic metastases of colorectal carcinoma  
26th Annual Meeting and Postgraduate Course of the Society of Gastrointestinal Radiologists  
Cancun, Mexico

03/1997

Phase I trial of sequential administration of Tomudex and 5-Iodo-5-Deoxyuridine (IdUrd).  
Vienna, Austria

09/1999

Use of measles virus F and H fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas 13th International Conference on Brain Tumor Research and Therapy Sapporo, Japan	10/1999
Phase I and pharmacological study of CCI-779, a cell cycle inhibitor NCI-EORTC-AACR Symposium Amsterdam, Netherlands	11/2000
Phase II trial of plasmid DNA/lipid (Leuvectin) immunotherapy in patients with metastatic renal cell carcinoma NCI-EORTC-AACR Symposium Amsterdam, Netherlands	11/2000
Phase I/II study of intra-arterial administration of a replication-selective adenovirus CI-1042 (onyx-015) in patients with metastatic colorectal carcinoma NCI-EORTC-AACR Symposium Amsterdam, Netherlands	11/2000
Use of vaccine strain of measles virus genetically engineered to produce CEA as a novel therapeutic agent against glioblastoma multiforme Fifth Congress of the European Association for Neuro-Oncology Florence, Italy	09/2002
A phase 2 trial of high-dose Allovectin-7 in patients with advanced metastatic melanoma. International Society for Biological Therapy of Cancer San Francisco, California	11/2004
Retargeted oncolytic measles virus strains displaying IL13 have significant antitumor activity against gliomas. Presented at the 14th Annual Congress of the European Society of Gene Therapy Athens, Greece	11/2006
Gastric spindle cell sarcomas may not be gastrointestinal stromal tumors: report of three cases of primary gastric synovial sarcoma with molecular confirmation. United States and Canadian Academy of Pathology's 96th Annual Meeting San Diego, California	03/2007
<b>National</b>	
Presence of IgG3 isotype of M2 antimitochondrial antibody suggests recurrence of primary biliary cirrhosis after orthotopic liver transplantation Meeting of the American Association for the Study of Liver Disease Chicago, Illinois	11/1993
Total joint arthroplasty in orthotopic liver transplant recipients 13th Annual Meeting of the Mid-America Orthopedic Association Pal m Beach, Florida	04/1995
Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer 31st Annual Meeting of the American Society of Clinical Oncology Los Angeles, California	05/1995



Prosthetic hip replacement for treatment of pathologic or impending pathologic fractures in multiple myeloma 63rd Annual Meeting of the American Academy of Orthopedic Surgeons Atlanta, Georgia	02/1996
Chemotherapy for advanced medulloblastoma and other CNS embryonal tumors in adults 48th Annual Meeting of the American Academy of Neurology San Francisco, California	03/1996
Chemotherapy for advanced embryonal tumors of the central nervous system in adults 32nd Annual Meeting of the American Society of Clinical Oncology Philadelphia, Pennsylvania	05/1996
Extrapulmonary small cell carcinoma 32nd Meeting of the American Society of Clinical Oncology Philadelphia, Pennsylvania	05/1996
Extrapulmonary small cell carcinoma: Epidemiology and response to treatment Biomedicine '96 Washington, District of Columbia	05/1996
Imaging-guided immunotherapy of hepatic metastases of colorectal carcinoma 82nd Annual Meeting of the Radiological Society of North America Chicago, Illinois	12/1996
Malignant tumors of the proximal fibula. A clinicopathological study of 93 patients 64th Annual Meeting of the American Academy of Orthopedic Surgeons San Francisco, California	02/1997
Benign tumors of the proximal end of the fibula. A clinicopathological study of 96 patients 64th Annual Meeting of the American Academy of Orthopedic Surgeons San Francisco, California	02/1997
Gliosarcoma: A glioblastoma multiforme variant? 88th Annual Meeting of the American Association for Cancer Research San Diego, California	04/1997
Immunotherapy with intratumoral injection of IL-2 DNA/DMRIE/DOPE lipid complex Molecular and Cellular Biology of Gene Therapy meeting Snowbird, Utah	04/1997
Management of recurrent meningeal hemangiopericytoma 33rd Annual Meeting of the American Society of Clinical Oncology Denver, Colorado	05/1997
Phase I/II trial of the IL-2 DNA/DMRIE/DOPE lipid complex as an immunotherapeutic agent by direct gene transfer in patients with advanced melanoma, renal cell carcinoma, and sarcoma. Sixth International Conference on Gene Therapy of Cancer San Diego, California	11/1997

Phase I/II trial of immunotherapy by direct gene transfer of the IL-2 DNA/DMRIE/DOPE lipid complex in patients with advanced melanoma, renal cell carcinoma and sarcoma. Molecular and Cellular Biology of Gene Therapy meeting Keystone, Colorado	01/1998
Phase I trial of sequential administration of Tomudex and 5-iodo-2-deoxyuridine (IdUrd). 89th Annual Meeting of the American Association for Cancer Research New Orleans, Louisiana	04/1998
Utility of neuroimaging, neurologic examination and symptom status in follow-up of high grade glioma patients 34th Annual Meeting of the American Society of Clinical Oncology Los Angeles, California	05/1998
Primary fibrosarcoma of the bone Combined Meeting of the American and European Musculoskeletal Society Washington, District of Columbia	05/1998
Distal fibulectomy for malignant and aggressive benign tumors Combined Meeting of the American and European Musculoskeletal Society Washington, District of Columbia	05/1998
Phase I/II trial of immunotherapy by direct gene transfer of the IL-1-DNA/DMRIE/DOPE lipid complex in patients with metastatic melanoma and renal cell carcinoma First Annual Meeting of the American Society of Gene Therapy Seattle, Washington	05/1998
Phase I trial of sequential administration of Tomudex and 5-iodo-2-deoxyuridine (IdUrd). 35th Annual Meeting of the American Society of Clinical Oncology Atlanta, Georgia	05/1999
Direct gene transfer of a plasmid encoding the IL-2 gene (Leuvectin) as treatment for patients with metastatic renal cell carcinomas (RCC) 35th Annual Meeting of the American Society of Clinical Oncology Atlanta, Georgia	05/1999
A phase I trial of MTA (multitargeted antifolate, LY231514) and gemcitabine (Gemzar) in patients with locally advanced or metastatic cancer 35th Annual Meeting of the American Society of Clinical Oncology Atlanta, Georgia	05/1999
Use of fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas Cytoreductive Gene Therapy Harold W. Siebens Conference Rochester, Minnesota	09/1999
Hepatic artery infusion of onyx-015 in combination with 5-FU/leukovorin for metastatic gastrointestinal cancer metastatic to the liver: A phase I/II study AACR/NCI/EORTC International Conference Washington, District of Columbia	10/1999

Fusogenic membrane glycoproteins as therapeutic transgenes in gliomas Fourth Annual Scientific Meeting of the Society for Neuro-Oncology Scottsdale, Arizona	11/1999
Fusogenic membrane glycoproteins as therapeutic transgenes in gliomas Fourth Annual Scientific Meeting of the Society for Neuro-Oncology Scottsdale, Minnesota	11/1999
Gene-based immunotherapy for cancer: Allovectin-7 and Leuvectin Mt. Sinai Chemotherapy Foundation Symposium XVII: Innovative Cancer Therapy for Tomorrow New York, New York	11/1999
A rapamycin analog and multifaceted inhibitor of signal transduction: A phase I study 36th Annual Meeting of the American Society of Clinical Oncology New Orleans, Louisiana	05/2000
Phase II trial of plasmid DNA/lipid (Leuvectin) immunotherapy in patients with metastatic renal cell carcinoma (RCC) 36th Annual Meeting of the American Society of Clinical Oncology New Orleans, Louisiana	05/2000
Limited activity and acceptable toxicity of gemcitabine in a phase II study of patients (Pts) with advanced sarcomas: A Mayo Cancer Center study 36th Annual Meeting of the American Society of Clinical Oncology New Orleans, Louisiana	05/2000
Hepatic artery infusion of onyx-015, a selectively-replicating adenovirus in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: A phase I/II trial 36th Annual Meeting of the American Society of Clinical Oncology New Orleans, Louisiana	05/2000
Use of fusogenic membrane glycoproteins as novel therapeutic transgene in gliomas Third Annual Meeting of the American Society of Gene Therapy Denver, Colorado	05/2000
Use of fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas Third Annual Meeting of the American Society of Gene Therapy Denver, Colorado	05/2000
Metalloproteinase cleavable linkers can target the cytotoxicity of fusogenic membrane glycoproteins in gliomas Cold Spring Harbor Laboratory Conference on Vector Targeting Cold Spring Harbor, New York	03/2001
Use of viral fusogenic membrane glycoproteins (FMG) as novel therapeutic transgenes in gliomas 37th Annual Meeting of the American Society of Clinical Oncology San Francisco, California	05/2001
Intra-arterial administration of a replication-selective adenovirus CI- 1042 (ONYX-015) in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biological activity 37th Annual Meeting of the American Society of Clinical Oncology San Francisco, California	05/2001

<p>Metalloproteinase cleavable linkers can target the cytotoxicity of fusogenic membrane glycoproteins in gliomas Fourth Annual Meeting of the American Society of Gene Therapy Seattle, Washington</p>	05/2001 - 06/2001
<p>Measles virus (MV-F and MV-H) and Gibbon ape leukemia virus (GALV.fus) deriving fusogenic membrane glycoproteins are potent transgenes in the gene therapy of gliomas Fourth Annual Meeting of the American Society of Gene Therapy Seattle, Washington</p>	05/2001 - 06/2001
<p>Phase I/II trial of ONYX-015 in combination with chemotherapy in patients with advanced sarcomas AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications Miami Beach, Florida</p>	10/2001 - 11/2001
<p>Phase I/II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas 93rd Annual Meeting of the American Association for Cancer Research San Francisco, California</p>	04/2002
<p>Intra-arterial administration of a replication-selective adenovirus Onyx-015 in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biological activity 93rd Annual Meeting of the American Association for Cancer Research San Francisco, California</p>	04/2002
<p>A controlled, randomized phase III trial comparing the response to the dacarbazine with and without Allovectin-7 in patients with metastatic melanoma 38th Annual Meeting of the American Society of Clinical Oncologists Orlando, Florida</p>	05/2002
<p>Intra-arterial administration of a replication-selective adenovirus ONYX-015 in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biological activity 38th Annual Meeting of the American Society of Clinical Oncologists Orlando, Florida</p>	05/2002
<p>Intraperitoneal therapy of ovarian cancer using an engineered measles virus Fifth Annual Meeting of the American Society of Gene Therapy Boston, Massachusetts</p>	06/2002
<p>Use of a vaccine strain of measles virus genetically engineered to produce CEA as a novel therapeutic agent against glioblastoma multiforme Fifth Annual Meeting of the American Society of Gene Therapy Boston, Massachusetts</p>	06/2002
<p>Intra-arterial administration of a replication-selective adenovirus ONYX-015 in patients with colorectal carcinoma metastatic to the liver: safety, feasibility and biologic activity. 39th Annual Meeting of the American Society of Clinical Oncology Chicago, Illinois</p>	05/31/2003 - 06/03/2003
<p>A phase II study of high-dose allovectin-7 patients with advanced metastatic melanoma. 39th Annual Meeting of the American Society of Clinical Oncology Chicago, Illinois</p>	05/31/2003 - 06/03/2003

Biodistribution of oncolytic recombinant Edmonston B measles virus in measles-susceptible mice. 6th Annual Meeting of the American Society of Gene Therapy Washington, District of Columbia	06/2003
Toxicology of oncolytic measles after intraperitoneal administration in measles-susceptible mice. 6th Annual Meeting of the American Society of Gene Therapy Washington, District of Columbia	06/2003
Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. 6th Annual Meeting of the American Society of Gene Therapy Washington, District of Columbia	06/2003
NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM). 40th Annual Meeting of the American Society of Clinical Oncology New Orleans, Louisiana	06/2004
A phase 2 trial of high-dose Allovectin-7 in patients with advanced metastatic melanoma. 40th Annual Meeting of the American Society of Clinical Oncology New Orleans, Louisiana	06/2004
Phase I Clinical Trials in Solid Tumors NCCTG Neuro-Oncology Program: North Central Cancer Treatment Group Meeting	09/2004
Development and Testing of Novel Gene and Virus Based Therapeutics NCCTG Neuro-Oncology Program: North Central Cancer Treatment Group Meeting	09/2004
Development of Cell Cycle Inhibitors as Novel Therapeutics in Malignant Gliomas NCCTG Neuro-Oncology Program: North Central Cancer Treatment Group Meeting	09/2004
Retargeting of Oncolytic Paramyxoviruses and Development of Preclinical Therapeutic Combinations with Small Molecule Inhibitors and Radiation Therapy NCCTG Neuro-Oncology Program: North Central Cancer Treatment Group Meeting	09/2004
NCCTG Neurooncology Program North Central Cancer Treatment Group Meeting	09/2004
N997B: Phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): updated and correlative laboratory analysis. American Society of Clinical Oncology Orlando, Florida	05/2005
High dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) in adults with relapsed CNS embryonal tumors. American Society of Clinical Oncology Orlando, Florida	05/2005
High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial. American Society of Clinical Oncology Orlando, Florida	05/2005

EGFRvIII retargeted oncolytic measles virus strains have significant antitumor activity against gliomas. American Society of Gene Therapy St. Louis, Missouri	06/2005
EGFRvIII Retargeting of Oncolytic Measles Virus Strains as an Antitumor Strategy Against Gliomas. American Society of Gene Therapy St. Louis, Missouri	07/2005
Phase II Trial of Irinotecan (CPT-11) and Radiation Followed by Irinotecan and BCNU in Glioblastoma Patients (pts). American Society of Clinical Oncology Atlanta, Georgia	06/2006
Phase I Trial of Intraperitoneal (IP) Administration of a Measles Virus (MV) Derivative Expressing the Human Carcinoembryonic Antigen (CEA) in Ovarian Cancer Patients. American Society of Clinical Oncology Atlanta, Georgia	06/2006
NCCTG 96-94-53: Clinical Variables Associated with Overall Survival (OS), Progression-free Survival (PFS), 6 Month Progression-free Survival (PFS6), Immediate Progression (ImmProg), and Response in Patients Enrolled in Recurrent Glioma Clinical Trials. American Society of Clinical Oncology Atlanta, Georgia	06/2006
Combination of Oncolytic Measles Virus Strains and Radiation Therapy has Synergistic Activity in the Treatment of Glioblastoma Multiforme American Society of Gene Therapy 9th Annual Meeting Baltimore, Maryland	06/01/2006
Safety of Repeat Intracerebral Administration of MV-CEA in Rhesus Macaques in Support of a Phase I/II Clinical Trial for Patients with Recurrent Gliomas American Society of Gene Therapy 9th Annual Meeting Baltimore, Maryland	06/01/2006
EGFRvIII Retargeted Oncolytic Measles Virus Strains have Significant Antitumor Activity Against Gliomas American Society of Gene Therapy 9th Annual Meeting Baltimore, Maryland	06/02/2006
Phase I Trial of Intraperitoneal (IP) Administration of a Measles Virus (MV) Strain Expressing the Human Carcinoembryonic Antigen (CEA) in Ovarian Cancer Patients. American Society of Gene Therapy 9th Annual Meeting Baltimore, Maryland	06/03/2006
Heat shock protein inhibitors increase the efficacy of measles virotherapy. American Society of Gene Therapy Seattle, Washington	06/01/2007
IL13 displaying retargeted oncolytic measles virus (MV) strains have significant activity and improved therapeutic index against gliomas. American Society of Gene Therapy Seattle, Washington	06/01/2007

North Central Cancer Treatment Group phase II trial of vorinostat (suberoylanilide hydroxamic acid) in patients with recurrent glioblastoma multiforme American Society of Clinical Oncology Chicago, Illinois	06/02/2007
Interleukin-13 displaying oncolytic measles virus strains have tumor-specific activity against gliomas with an improved therapeutic index. 15th Annual SPORE Investigators Workshop Baltimore, Maryland	07/09/2007
NCCTG Neurooncology Program: Towards Novel Targets and Molecular Therapeutics NCCTG Symposium	09/27/2007
Oncolytic measles virus derivatives have significant antitumor activity against prostate cancer. American Society of Gene Therapy 11th Annual Meeting Boston, Massachusetts	05/2008
Oncolytic measles virus strains are effective therapy for malignant pleural effusions in a xenograft model of advanced breast cancer. American Society of Gene Therapy 11th Annual Meeting Boston, Massachusetts	05/2008
Phase I trial of intraperitoneal (IP) administration of an oncolytic measles virus (MV) derivative, expressing the human carcinoembryonic antigen (CEA) in patients with advanced ovarian cancer (OvCa). American Society of Gene Therapy 11th Annual Meeting Boston, Massachusetts	05/2008

## INVITED PRESENTATIONS AND VISITING PROFESSORSHIPS

### Invited Presentations

Brain tumors UMB Chapter of AANN	04/2000
Gene therapy for cancer: From basic research to clinical practice Greek Society for Medical Studies Athens, Greece	12/2000
Gene therapy for sarcomas 14th Orthopedic Oncology Meeting, Hellenic Association of Orthopaedic Surgery and Traumatology, Section of Oncology Iliias, Greece	06/2001
Present and future status of gene therapy in cancer 9th Annual Postgraduate Course in Clinical Oncology Crete, Greece	11/2001
Phase I/II study of Onyx-015 in combination with MAP chemotherapy in patients with advanced sarcomas National Cancer Institute CTEP Drug Development Fall 2002 Phase I Meeting Washington, District of Columbia	10/2002
Novel Therapeutics in Adult Brain Tumor 10th Annual Postgraduate Course in Clinical Oncology Crete, Greece	11/2002

Cancer Gene Therapy 1st Medical Conference: Cancer: Present Advances & Future Perspectives Hygeia, Greece	06/2003
Advances in Oncology: Gene Therapy Centro Hemato-oncologico/University of Panama Panama City, Panama	09/2003
Cancer Gene Therapy/Virotherapy Trials: Immunologic Endpoints Mayo Clinic Immunotherapy Group	10/2003
Neuro-Oncology Program North Central Cancer Treatment Group Medical Oncology Committee Meeting	10/2003
Novel Therapeutic Approaches in the Treatment of Sarcomas 11th Annual Postgraduate Course in Clinical Oncology Crete, Greece	11/2003
Fusogenic Membrane Glycoproteins: From the Bench to the Clinic University of Ioannina Biomedical Research Institute: Interdisciplinary Seminar Series Ioannina, Greece	04/2004
Her-2/c-neu as a Therapeutic Target in Oncology Neuroendocrine Differentiation in Cancer: Molecular Data and Clinical Significance. Gythion, Greece	07/2004
Measles Virus in Cancer Treatment Round Table Discussion on Viral Gene Therapy of Human Cancers Dallas, Texas	03/2005
Phase I Trials of Oncolytic Measles Virus Strains The 3rd International Meeting on Replicating Oncolytic Virus Therapeutics. Banff, Alberta, Canada	03/2005
Measles Virus The Preuss Foundation Seminar on Oncolytic Viral Therapies for Brain Tumors La Jolla, California	11/2005
Measles Virus for the Treatment of Ovarian Cancer International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Chicago, Illinois	11/2005
Measles Virus in the Treatment of Gliomas. Prashant & Saloni Fadia International Hermelin Brain Tumor Center Symposium on Oncolytic Viral Therapy. Henry Ford Hospital. Detroit, Michigan	11/2005
GCRC based Cancer Gene Therapy and Virotherapy Trials at the Mayo Clinic. GCRC 35th Anniversary Event Rochester, Minnesota	03/29/2006
Chemotherapy in the Management of Soft Tissue Sarcomas. 19th Annual Hellenic Meeting of the Orthopaedic Oncology with International Participation Athens, Greece	05/06/2006



Human Papilloma Virus and Cervical Cancer. Alaska Native Medical Center/Mayo Clinic Cancer Center Cancer Conference Anchorage, Alaska	07/2006
Gene Therapy for Ovarian Cancer Mayo Clinic Board Reviews Amelia Island, Florida	08/2006
Virotherapy Approaches in the Treatment of Cancer The Infectious Basis of Cancer: Pathogenic Insight and Therapeutic Opportunities. Rochester, Minnesota	09/2006
Initial Data of a Phase I Trial of the Measles Virus Derivative MV-CEA in Patients with Recurrent Ovarian Cancer Fourteenth International Conference on Gene Therapy of Cancer Dallas, Texas	09/2006
Oncolytic Measles Virus Strains in Glioma Treatment TIB Lecture Series Rochester, Minnesota	03/12/2007
Clinical Experience with Oncolytic Measles Virus Strains The 4th International Conference on Oncolytic Viruses as Cancer Therapeutics Carefree, Arizona	03/15/2007
Gene Therapy and Virotherapy in the Treatment of Malignant Gliomas Glioblastoma Multiforme Workshop, Arizona Cancer Center Tucson, Arizona	03/17/2007
Virotherapy with Oncolytic Measles Virus Strains in the Treatment of Malignant Gliomas Translational Immunovirology and Biodefense Series Rochester, Minnesota	03/17/2007
Oncolytic Measles Virus Strains as Cancer Therapeutics: From the Bench to the Bedside 2nd Panhellenic Congress on Biotechnology and Food Technology Athens, Greece	03/31/2007
Adjuvant Treatment Modalities in the Management of Sarcomas IV Congress of the World Society for Reconstructive Microsurgery Athens, Greece	06/26/2007
Clinical experience with oncolytic measles virus strains Measles Virus Mini-Symposium Rochester, Minnesota	09/14/2007
Chemotherapy in the Management of Soft Tissue Sarcomas Athens, Greece	11/21/2007
Histone Deacetylase Inhibitor: Vorinostat IV International Conference on Future Trends in the Treatment of Brain Tumors Bologna, Italy	02/22/2008
Clinical Trials with Engineered Oncolytic Measles Virus Strains American Society of Gene Therapy Boston, Massachusetts	05/31/2008

## RESEARCH INTERESTS

- \* Development and testing of novel gene and virus-based therapeutics as antitumor agents.
- \* Development of cell cycle inhibitors as novel therapeutics in malignant gliomas.
- \* Retargeting of oncolytic paramyxoviruses and testing of therapeutic combinations with small molecule inhibitors and radiation therapy.
- \* Phase I clinical trials in solid tumors.

## RESEARCH GRANTS AWARDED

### Active Grants

#### Federal

	N047B, A Phase II Trial of Suberoylanilide Hydroxamic Acid (SAHA) in Patients with Recurrent Glioblastoma. Funded by National Institutes of Health. (U01 N047B)	07/2006 - 07/2008
	Scientific Review Panels in: Mayo Clinic Center for Clinical and Translational Research. Funded by National Center for Research Resources. (UL1 RR 24150)	09/2006 - 06/2011
Principal Investigator	BT SPORE - Project 2 - AMVGT in: Mayo SPORE in Brain Cancer. Funded by National Cancer Institute. (P50 CA 108961)	09/2004 - 08/2009
Principal Investigator	Measles Virotherapy for Glioblastoma Multiforme. Funded by National Institutes of Health. (R21 CA 123839)	08/2006 - 07/2008
Principal Investigator	Prostate Cancer SPORE Development/Career Development Project (CA91956-07) "Engineered Measles Virus as Novel Oncolytic Therapy for Prostate Cancer". Funded by National Institutes of Health. (P50 CA91956 )	09/2007 - 08/2008
Co-Investigator	Phase I Clinical Trials of Anticancer Agents. Funded by National Cancer Institute. (U01 CA 69912)	06/1995 - 06/2008
Co-Investigator	Use of Fusogenic Membrane Glycoproteins for Gene Therapy of Prostate Cancer in: SPORE in Prostate Cancer. Funded by National Cancer Institute. (P50 CA 91956)	08/2001 - 08/2011
Consultant	Vuk-Pavlovic - Phase II Clinical Trial of an allogenic whole cell vaccine administered with autologous myeloid dendritic cells in: SPORE in Prostate Cancer. Funded by National Cancer Institute. (P50 CA 91956)	09/2006 - 08/2011

#### Foundation

Principal Investigator	------(b)(4)----- for Breast Cancer in: Atwater Gift. Funded by Development.	05/2006 - 04/2011
------------------------	--	-------------------

Principal Investigator	(b)(4)- - A Phase II Trial of (b)(4)- ----- -----, Funded by Merck Research Laboratories. (MERCK (b)(4)-)	12/2007 - 05/2009
------------------------	--	-------------------

## Federal

Principal Investigator	Biological Evaluation of CC1-779 in Brain Tumors. Funded by National Institutes of Health. (R21 CA 99209)	06/2002 - 05/2005
------------------------	--	-------------------

## Foundation

Principal Investigator -----(b)(4)----- 11/2001 - 10/2004  
----- in Preclinical Models of  
Breast Cancer. Funded by Prospect Creek  
Foundation. (PROSPECT -(b)(4)-)

Principal Investigator	Eagles' Cancer Fund. Funded by Eagles Fund. (EAGLES -(b)(4)-)	11/2002 - 12/2003
------------------------	--	-------------------

Principal Investigator	-----(b)(4)----- in the Treatment of Ovarian Cancer. Funded by Goodwin Funds.	01/2006 - 12/2006
------------------------	--	-------------------

Principal Investigator -----(b)(4)----- 05/1998 - 06/2004  
-----  
-----  
-----  
-----  
Funded by VICAL Incorporated. (Vical -(b)(4)-)

Principal Investigator -----(b)(4)----- 07/1998 - 12/2004  
-----  
-----  
-----, Funded by  
VICAL Incorporated. (Vical -(b)(4)-)

Principal Investigator -----(b)(4)----- 10/1999 - 09/2004  
-----, Funded by  
VICAL Incorporated. (VICAL -(b)(4)-)

Principal Investigator	----- (b)(4) ----- ----- ----- . Funded by VICAL Incorporated. (VICAL - (b)(4) -)	05/2000 - 04/2006
Principal Investigator	----- (b)(4) ----- ----- Funded by VICAL Incorporated. (VICAL - (b)(4) -)	07/2000 - 06/2004
Principal Investigator	----- (b)(4) ----- ----- ----- . Funded by Parke-Davis. (PARKE - (b)(4) -)	11/2000 - 10/2001
Principal Investigator	(b)(4) ----- ----- ----- . Funded by VICAL Incorporated. (VICAL - (b)(4) -)	08/2001 - 07/2004
Principal Investigator	----- (b)(4) ----- ----- ----- ----- ----- Funded by MediGene. (MEDIGENE --- (b)(4) ---)	04/2005 - 03/2009
Principal Investigator	----- (b)(4) ----- ----- ----- ----- ----- . Funded by Epeius Biotechnologies. (EPEIUS ----- (b)(4) -----)	07/2005 - 06/2008
<b>Mayo Clinic</b>		
Principal Investigator	Phase I/II Study of Combination of MAP with ONYX 015 in Patients With Advanced Sarcoma. Funded by CR Programs.	10/1999 - 09/2003

## PATENTS

Title	Patent number	Date filed	Date issued
Pharmacodiagnostic Test for mTOR Inhibitors in Cancer Patients Inventors: Galanis E	US 60680776	05/21/2006	05/21/2006

## BIBLIOGRAPHY

### Peer-reviewed Articles

1. Galanis E. Infectious endocarditis: Prognosis, prophylaxis, treatment. *Topics in Cardiology* 1989; 83.
2. Papagelopoulos P, Galanis E, Shaughnessy WJ, Currier BL, Sim FH, Unni KK. Aneurysmal bone cysts of the cervical spine. *Acta Orthopaedica Hellenica* 1994; 45(4):214-223.
3. Papagelopoulos PJ, Hay JE, Galanis EC, Morrey BF. Total joint arthroplasty in orthotopic liver transplant recipients. *J Arthroplasty* 1996 Dec; 11(8):889-92.
4. Rubin J, Galanis E, Pitot HC, Richardson RL, Burch PA, Charboneau JW, Reading CC, Lewis BD, Stahl S, Akporiaye ET, Harris DT. Phase I study of immunotherapy of hepatic metastases of colorectal carcinoma by direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7. *Gene Ther* 1997 May; 4(5):419-25.
5. Galanis E, Frytak S, Lloyd RV. Extrapulmonary small cell carcinoma. *Cancer* 1997 May 1; 79(9):1729-36.
6. Galanis E, Buckner JC, Schomberg PJ, Hammack JE, Raffel C, Scheithauer BW. Effective chemotherapy for advanced CNS embryonal tumors in adults. *J Clin Oncol* 1997 Aug; 15(8):2939-44.
7. Papagelopoulos PJ, Galanis EC, Greipp PR, Sim FH. Prosthetic hip replacement for pathologic or impending pathologic fractures in myeloma. *Clin Orthop* 1997 Aug; 341:192-205.
8. Galanis E, Litzow MR, Tefferi A, Scott JP. Spontaneous pneumomediastinum in a patient with bronchiolitis obliterans after bone marrow transplantation. *Bone Marrow Transplant* 1997 Oct; 20(8):695-6.
9. Galanis E, Hartmann LC. Granulocyte colony-stimulating factor in severe chemotherapy induced afebrile neutropenia. *Topics Support Care Oncol* 1998; 26:12-3.
10. Galanis E. Cancer gene therapy: an overview based on the first annual meeting of the American Society of Gene Therapy. *Tumor Targeting* 1998; 3(3):191-194.
11. Skarin A, Galanis E, Kvols LK, Rubin J. Diagnosis in oncology. *J Clin Oncol* 1998; 16(2):796-798.
12. Galanis E, Kvols LK, Rubin J. Carcinoid syndrome. *J Clin Oncol* 1998 Feb; 16(2):796-8.
13. Papagelopoulos PJ, Galanis EC, Sim FH, Unni KK. Osteoblastoma of the acetabulum. *Orthopedics* 1998 Mar; 21(3):355-8.
14. Galanis E, Buckner JC, Scheithauer BW, Kimmel DW, Schomberg PJ, Piepgras DG. Management of recurrent meningeal hemangiopericytoma. *Cancer* 1998 May 15; 82(10):1915-20.
15. Galanis E, Buckner JC, Burch PA, Schaefer PL, Dinapoli RP, Novotny PJ, Scheithauer BW, Rowland KM, Vukov AM, Mailliard JA, Morton RF. Phase II trial of nitrogen mustard, vincristine, and procarbazine in patients with recurrent glioma: North Central Cancer Treatment Group results. *J Clin Oncol* 1998 Sep; 16(9):2953-8.

16. Galanis E, Buckner JC, Dinapoli RP, Scheithauer BW, Jenkins RB, Wang CH, O'Fallon JR, Farr G Jr. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: North Central Cancer Treatment Group results. *J Neurosurg* 1998 Sep; 89(3):425-30.
17. Galanis E, Buckner J, Kimmel D, Jenkins R, Alderete B, O'Fallon J, Wang CH, Scheithauer BW, James CD. Gene amplification as a prognostic factor in primary and secondary high-grade malignant gliomas. *Int J Oncol* 1998 Oct; 13(4):717-24.
18. Papagelopoulos PJ, Galanis E, Sim FH, Unni KK. Mayo Clinic tumor rounds: periosteal osteosarcoma. *Orthopedics* 1999; 22(10):971-974.
19. Papagelopoulos PJ, Galanis E, Sim FH, Unni KK. Periosteal osteosarcoma. *Orthopedics* 1999; 10:971-4.
20. Papagelopoulos PJ, Currier BL, Galanis EC, Sim FH. Vertebra plana of the lumbar spine caused by an aneurysmal bone cyst: a case report. *Am J Orthop (Chatham, NJ)* 1999 Feb; 28(2):119-24.
21. Papagelopoulos PJ, Galanis EC, Sim FH, Unni KK. Clinicopathologic features, diagnosis, and treatment of osteoblastoma. *Orthopedics (Thorofare, NJ)* 1999 Feb; 22(2):244-7; quiz 248-9.
22. Galanis E, Frytak S, Rowland KM Jr, Sloan JA, Lennon VA. Neuronal autoantibody titers in the course of small-cell lung carcinoma and platinum-associated neuropathy. *Cancer Immunol Immunother* 1999 May-Jun; 48(2-3):85-90.
23. James CD, Galanis E, Frederick L, Kimmel DW, Cunningham JM, Atherton-Skaff PJ, O'Fallon JR, Jenkins RB, Buckner JC, Hunter SB, Olson JJ, Scheithauer BW. Tumor suppressor gene alterations in malignant gliomas: histopathological associations and prognostic evaluation. *Int J Oncol* 1999 Sep; 15(3):547-53.
24. Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Burch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J. Immunotherapy of advanced malignancy by direct gene transfer of an interleukin-2 DNA/DMRIE/DOPE lipid complex: phase I/II experience. *J Clin Oncol* 1999 Oct; 17(10):3313-23.
25. Papagelopoulos PJ, Galanis E, Vlastou C, Nikiforidis PA, Vlamis JA, Boscainos PJ, Fragiadakis EG, Stamos KG, Pantazopoulos T, Sim FH. Current concepts in the evaluation and treatment of osteosarcoma. *Orthopedics* 2000; 23:858-67.
26. Papagelopoulos PJ, Galanis EC, Sim FH, Unni KK. Clinicopathologic features, diagnosis, and treatment of malignant fibrous histiocytoma of bone. *Orthopedics (Thorofare, NJ)* 2000 Jan; 23(1):59-65; quiz 66-7.
27. Galanis E, Buckner J. Chemotherapy for high-grade gliomas. *Br J Cancer* 2000 Apr; 82(8):1371-80.
28. Papagelopoulos PJ, Galanis E, Frassica FJ, Sim FH, Larson DR, Wold LE. Primary fibrosarcoma of bone. Outcome after primary surgical treatment. *Clin Orthop* 2000 Apr; 373:88-103.
29. Galanis E, Buckner JC, Novotny P, Morton RF, McGinnis WL, Dinapoli R, Schomberg P, O'Fallon JR. Efficacy of neuroradiological imaging, neurological examination, and symptom status in follow-up assessment of patients with high-grade gliomas. *J Neurosurg* 2000 Aug; 93(2):201-7.
30. Galanis E, Alberts SR, O'Connell MJ. New adjuvant therapy for colon cancer: justified hope or commercial hype. *Surg Oncol Clin N Am* 2000 Oct; 9(4):813-23; discussion 825-6.

31. Galanis E, Buckner JC. Chemotherapy of brain tumors. *Curr Opin Neurol* 2000 Dec; 13(6):619-25.
32. Daniels GA, Galanis E. Immunotherapy of renal cell carcinoma by intratumoral administration of an IL-2 cDNA/DMRIE/DOPE lipid complex. *Curr Opin Mol Ther* 2001 Feb; 3(1):70-6.
33. Galanis E, Goldberg R, Reid J, Atherton P, Sloan J, Pitot H, Rubin J, Adjei AA, Burch P, Safgren SL, Witzig TE, Ames MM, Erlichman C. Phase I trial of sequential administration of raltitrexed (Tomudex) and 5-iodo-2'-deoxyuridine (IdUrd). *Ann Oncol* 2001 May; 12(5):701-707.
34. Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. *Hum Gene Ther* 2001 May 1; 12(7):811-21.
35. Galanis E, Vile R, Russell SJ. Delivery systems intended for in vivo gene therapy of cancer: targeting and replication competent viral vectors. *Crit Rev Oncol Hematol* 2001 Jun; 38(3):177-92.
36. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Romel L, Hatfield M, Rubin J, Kirn D. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. *Gene Ther* 2001 Nov; 8(21):1618-26.
37. Galanis E, Russell S. Cancer gene therapy clinical trials: lessons for the future. *Br J Cancer* 2001 Nov 16; 85(10):1432-6.
38. Galanis E. Technology evaluation: Allovectin-7, Vical. *Curr Opin Mol Ther* 2002 Feb; 4(1):80-7.
39. Papagelopoulos PJ, Galanis EC, Trantafyllidis P, Boscainos PJ, Sim FH, Unni KK. Clinicopathologic features, diagnosis, and treatment of fibrosarcoma of bone. *Am J Orthop* 2002 May; 31(5):253-7.
40. Papagelopoulos PJ, Currier BL, Galanis E, Grubb MJ, Pritchard DJ, Ebersold MJ. Vertebra plana caused by primary Ewing sarcoma: Case report and review of the literature. *Journal of Spinal Disorders & Techniques* 2002 Jun; 15(3):252-7.
41. Okuno S, Edmonson J, Mahoney M, Buckner JC, Frytak S, Galanis E. Phase II trial of gemcitabine in advanced sarcomas. *Cancer* 2002 Jun 15; 94(12):3225-9.
42. Papagelopoulos PJ, Galanis EC, Boscainos PJ, Bond JR, Unni KK, Sim FH. Periosteal chondrosarcoma. *Orthopedics* 2002 Aug; 25(8):839-42.
43. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. *Cancer Res* 2002 Aug 15; 62(16):4656-62.
44. Reid T, Galanis E, Abbruzzese J, Sze D, Wein LM, Andrews J, Randlev B, Heise C, Uprichard M, Hatfield M, Rome L, Rubin J, Kirn D. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints. *Cancer Res* 2002 Nov 1; 62(21):6070-9.
45. Mavrogenis AF, Papagelopoulos PJ, Galanis EC, Psicharis IP, Savvidou OD, Karavolias C, Linardaki E. Molecular biology of bone tumors. *Ostoun* 2003; 14(2):102-109.
46. Papadopoulos EC, Papagelopoulos PJ, Galanis EC, Savvidou OD, Karavolias CE, Mavrogenis AF. Epidemiological data, diagnosis and treatment of Ewing sarcoma. *Ostoun* 2003; 14(2):125-131.

47. Savvidou OD, Papagelopoulos PJ, Galanis EC, Boscainos PJ, Papdopoulos EC, Triantafillopoulos IK. Malignant fibrous histiocytoma of bone. Diagnosis and Treatment. *Ostoun* 2003; 14(2):132-139.
48. Savvidou OD, Papagelopoulos PJ, Galanis EC, Papdopoulos HC, Boscainos PJ, Karavolias CE. Current concepts on treatment and prognosis of osteosarcoma. *Ostoun* 2003; 14(2):110-117.
49. Hamid O, Varterasian ML, Wadler S, Hecht JR, Benson A, Galanis E, Uprichard M, Omer C, Bycott P, Hackman RC, Shields AF. Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer. *J Clin Oncol* 2003 Apr 15; 21(8):1498-504.
50. Johnson KJ, Peng KW, Allen C, Russell SJ, Galanis E. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. *Gene Ther* 2003 May; 10(9):725-32.
51. Papagelopoulos PJ, Savvidou OD, Galanis EC, Wenger DE, Inwards CY, Sim FH. Erdheim-Chester disease. *Orthopedics* 2003 May; 26(5):505-8.
52. Phuong LK, Allen C, Peng KW, Giannini C, Greiner S, TenEyck CJ, Mishra PK, Macura SI, Russell SJ, Galanis EC. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. *Cancer Res* 2003 May 15; 63(10):2462-9.
53. Goetz MP, Erlichman C, Windebank AJ, Reid JM, Sloan JA, Atherton P, Adjei AA, Rubin J, Pitot H, Galanis E, Ames MM, Goldberg RM. Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, fluorouracil, and leucovorin in patients with solid tumors. *J Clin Oncol* 2003 Oct 15; 21(20):3761-9.
54. Peng KW, Frenzke M, Myers R, Soeffker D, Harvey M, Greiner S, Galanis E, Cattaneo R, Federspiel MJ, Russell SJ. Biodistribution of oncolytic measles virus after intraperitoneal administration into Ifnar (TM)-CD46Ge transgenic mice. *Hum Gene Ther* 2003 Nov; 14(16):1565-77.
55. Savvidou OD, Papagelopoulos PJ, Galanis EC, Inwards CY, Wenger DE, Sim FH. Erdheim-Chester disease: a rare lipid granulomatosis. *Orthopedics* 2004; 27(7):1-5.
56. Papagelopoulos PJ, Mavrogenis AF, Currier BL, Katonis P, Galanis EC, Sapkas GS, Korres DS. Primary malignant tumors of the cervical spine. *Orthopedics* 2004 Oct; 27(10):1066-75.
57. Allen C, McDonald C, Giannini C, Peng KW, Rosales G, Russell SJ, Galanis E. Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas. *J Gene Med* 2004 Nov; 6(11):1216-27.
58. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Savvidou OD, Boscainos PJ, Katonis PG, Sim FH. Chordoma of the spine: Clinicopathological features, diagnosis, and treatment. *Orthopedics* 2004 Dec; 27(12):1256-63.
59. Galanis E, Burch PA, Richardson RL, Lewis B, Pitt HC, Frytak S, Spier C, Akporiaye ET, Peethambaram PP, Kaur JS, Okuno SH, Unni KK, Rubin J. Intratumoral administration of a 1,2-dimyristyloxypropyl-3-dimethylhydroxyethyl ammonium bromide/dioleoylphosphatidylethanolamine formulation of the human interleukin-2 gene in the treatment of metastatic renal cell carcinoma. *Cancer* 2004 Dec 1; 101(11):2557-66.



60. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Chloros GD, Papaparaskeva KT. Malignant fibrous histiocytoma of bone associated with type-1 neurofibromatosis. A case report J Bone Joint Surg Am 2005; 87(2):399-403.
61. Galanis E, Okuno SH, Nascimento AG, Lewis BD, Lee RA, Oliveira AM, Sloan JA, Atherton P, Edmonson JH, Erlichman C, Randlev B, Wang Q, Freeman S, Rubin J. Phase I-II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. Gene Ther 2005 Mar; 12(5):437-45.
62. Giannini C, Sarkaria JN, Saito A, Uhm JH, Galanis E, Carlson BL, Schroeder MA, James CD. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro-oncol 2005 Apr; 7(2):164-76.
63. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Kelekis NL, Wenger DE, Sim FH, Soucacos PN. Minimally invasive techniques in orthopedic oncology: Radiofrequency and laser thermal ablation. Orthopedics 2005 Jun; 28(6):563-8.
64. Papagelopoulos PJ, Savvidou OD, Mavrogenis AF, Galanis EC, Shaughnessy WJ, Unni KK, Sim FH. Lateral malleolus en bloc resection and ankle reconstruction for malignant tumors. Clin Orthop Relat Res 2005 Aug; (437):209-18.
65. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, Boni J, Peralba JM, Jenkins RB, Dakhil SR, Morton RF, Jaeckle KA, Scheithauer BW, Dancey J, Hidalgo M, Walsh DJ. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. J Clin Oncol 2005 Aug 10; 23(23):5294-304.
66. Galanis E, Buckner JC, Maurer MJ, Reid JM, Kuffel MJ, Ames MM, Scheithauer BW, Hammack JE, Pipoly G, Kuross SA. Phase I/II trial of pyrazoloacridine and carboplatin in patients with recurrent glioma: A North Central Cancer Treatment Group trial. Invest New Drugs 2005 Oct; 23(5):495-503.
67. Papagelopoulos PJ, Mavrogenis AF, Mitsiokapa EA, Papaparaskeva KT, Galanis EC, Soucacos PN. Current trends in the management of extra-abdominal desmoid tumours. World J Surg Oncol 2006; 4:21-29.
68. Papagelopoulos PJ, Mavrogenis AF, Chloros GD, Galanis EC, Papaparaskeva KT. A 60-year-old man with right hip pain. Clin Orthop Relat Res 2006 Feb; 443:342-9.
69. Galanis E, Buckner JC, Maurer MJ, Sykora R, Castillo R, Ballman KV, Erickson BJ. Validation of neuroradiologic response assessment in gliomas: Measurement by RECIST, two-dimensional, computer-assisted tumor area, and computer-assisted tumor volume methods. Neuro-oncol 2006 Apr; 8(2):156-65.
70. Papagelopoulos PJ, Mavrogenis AF, Kelekis AD, Katonis P, Galanis EC, Wenger DE, Sim FH, Soucacos PN. Percutaneous osteoplasty for pelvic and spine metastases. Orthopedics 2006 Apr; 29(4):316-23.
71. Papagelopoulos PJ, Galanis EC, Mavrogenis AF, Savvidou OD, Bond JR, Unni KK, Sim FH. Survivorship analysis in patients with periosteal chondrosarcoma. Clin Orthop Relat Res 2006 Jul; 448:199-207.
72. Papagelopoulos PJ, Savvidou OD, Galanis EC, Mavrogenis AF, Jacofsky DJ, Frassica FJ, Sim FH. Advances and challenges in diagnosis and management of skeletal metastases. Orthopedics 2006 Jul; 29(7):609-20.

73. McDonald CJ, Erlichman C, Ingle JN, Rosales GA, Allen C, Greiner SM, Harvey ME, Zollman PJ, Russell SJ, Galanis E. A measles virus vaccine strain derivative as a novel oncolytic agent against breast cancer. *Breast Cancer Res Treat* 2006 Sep; 99(2):177-84.
74. Simpson L, Galanis E. Recurrent glioblastoma multiforme: advances in treatment and promising drug candidates. *Expert Rev Anticancer Ther* 2006 Nov; 6(11):1593-607.
75. Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Peng KW, Goble JM, Uhm JH, Russell SJ, Galanis E. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. *Cancer Res* 2006 Dec 15; 66(24):11840-50.
76. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. *Nat Clin Pract Oncol* 2007 Feb; 4(2):101-17.
77. Papagelopoulos PJ, Mavrogenis AF, Galanis EC, Savvidou OD, Inwards CY, Sim FH. Clinicopathological features, diagnosis, and treatment of adamantinoma of the long bones. *Orthopedics* 2007 Mar; 30(3):211-5; quiz 216-7.
78. Sarkaria JN, Yang L, Grogan PT, Kitange GJ, Carlson BL, Schroeder MA, Galanis E, Giannini C, Wu W, Dinca EB, James CD. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel. *Mol Cancer Ther* 2007 Mar; 6(3):1167-74.
79. Paraskevakou G, Allen C, Nakamura T, Zollman P, James CD, Peng KW, Schroeder M, Russell SJ, Galanis E. Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR- or EGFRvIII expressing gliomas. *Mol Ther* 2007 Apr; 15(4):677-86.
80. Liu C, Sarkaria JN, Petell CA, Paraskevakou G, Zollman PJ, Schroeder M, Carlson B, Decker PA, Wu W, James CD, Russell SJ, Galanis E. Combination of measles virus virotherapy and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. *Clin Cancer Res* 2007 Dec 1; 13(23):7155-65.
81. -----(b)(4)-----  
-----  
-----
82. D'Assoro AB, Busby R, Acu ID, Quatraro C, Reinholz MM, Farrugia DJ, Schroeder MA, Allen C, Stivala F, Galanis E, Salisbury JL. Impaired p53 function leads to centrosome amplification, acquired ERa phenotypic heterogeneity and distant metastases in breast cancer MCF-7 xenografts. *Oncogene* 2008. Epub Feb 11.
83. Liu C, Erlichman C, McDonald CJ, Ingle JN, Zollman P, Iankov I, Russell SJ, Galanis E. Heat shock protein inhibitors increase the efficacy of measles virotherapy. *Gene Ther* 2008; 15(14):1024-34. Epub 2008 Mar 20.
84. Raffel C, Kreofsky C, Galanis E, Giannini C, Russell S. Treatment of medulloblastoma with modified measles virus. *J Neurosurg Pediatrics* 2008; 1(4):A353-4.
85. Tan TS, Walia T, Galanis E, Goetz MP, Rubin J, Jatoti A. If you hold it off-hours, will they come? Results from a feasibility project intended to stimulate interest in the physician-investigator career path among medical oncology trainees. *J Cancer Edu* 2008.

86. Yang L, Clarke MJ, Carlson BL, Mladek AC, Schroeder MA, Decker P, Wu W, Kitange GJ, Grogan PT, Goble JM, Uhm J, Galanis E, Giannini C, Lane HA, James CD, Sarkaria JN. PTEN loss does not predict for response to RAD001 (Everolimus) in a glioblastoma orthotopic xenograft test panel. *Clin Cancer Res* 2008; 14(12):3993-4001.
87. Allen C, Paraskevakou G, Liu C, Iankov ID, Zollman P, Galanis E. Oncolytic measles virus strains in the treatment of gliomas. *Expert Opin Biol Ther* 2008 Feb; 8(2):213-20.
88. Papagelopoulos PJ, Mavrogenis AF, Savvidou OD, Benetos IS, Galanis EC, Soucacos PN. Pathological fractures in primary bone sarcomas. *Injury* 2008 Apr; 39(4):395-403. Epub 2007 Dec 03.
89. Gill P, Litzow M, Buckner J, Arndt C, Moynihan T, Christianson T, Ansell S, Galanis E. High-dose chemotherapy with autologous stem cell transplantation in adults with recurrent embryonal tumors of the central nervous system. *Cancer* 2008 Apr 15; 112(8):1805-11.
90. Galanis E, Carlson SK, Foster NR, Lowe V, Quevedo F, McWilliams RR, Grothey A, Jatoi A, Alberts SR, Rubin J. Phase I trial of a pathotropic retroviral vector expressing a cytotoxic cyclin G1 construct (Rexin-G) in patients with advanced pancreatic cancer. *Mol Ther* 2008 May; 16(5):979-84. Epub 2008 Mar 18.
91. Myers R, Harvey M, Kaufmann TJ, Greiner SM, Krempski JW, Raffel C, Shelton SE, Soeffker D, Zollman P, Federspiel MJ, Blanco M, Galanis E. Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in Rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. *Human Gene Ther* 2008 Jun 24. Epub ahead of print.
92. Reddi HV, Madde P, Reichert-Eberhardt AJ, Galanis EC, Copland JA, McIver B, Grebe SK, Eberhardt NL. ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice. *Cancer Gene Ther* 2008 June 27. Epub ahead of print.

### Book Chapters

1. Galanis E. Ancient Greek medicine: from Homer to Hippocrates. In: Honorary Edition for Professor Emeritus G Daikos 1988; 487.
2. Papagelopoulos PJ, Galanis EC, McDonald DJ, Sim FH. Fibrosarcoma of bone. In: *Oxford Textbook of Orthopedics and Trauma*, Oxford University Press, Oxford, England, 1996.
3. Galanis E, James CD. Brain tumors. In: Kurzrock R, Talpaz M, editors. *Molecular Biology in Cancer Medicine*. London: Martin Dunitz; 1999. p. 273-86.
4. Galanis E. Cancer gene therapy: From basic research to clinical practice. Pages 49-53 in: Honorary Edition for Professor Emeritus B. Golematis, 1999.
5. Algan O, Nelson DF, Dinapoli RP, Galanis E, Raffel C, Parisi JE, Buckner JC, Jenkins RB. High-grade gliomas. In: Gunderson LL, Tepper JE, editors. *Clinical Radiation Oncology*. New York: Churchill Livingstone; 2000. p. 355-78.
6. Galanis E, Rubin J. Intratumoral gene transfer of the HLA-B7 gene into colon carcinoma metastases. In: *Intratumoral gene transfer of the HLA-B7 gene into colon carcinoma metastases. Methods in Molecular Medicine 35: Gene Therapy: Methods and Protocols 1st Edition*, Humana Press, 2000; pp 453-467.

7. Galanis E. Supportive measures: Carcinoma metastatic to bone. Chapter 36, 331-41 in: OKU: Musculoskeletal Tumors. L.R. Menendez, Editor. American Association of Orthopedic Surgeons, 2001.
8. Papagelopoulos PJ, Galanis E, McDonald D, Sim FH. Fibrosarcoma of bone. Chapter, 283-288 in: Oxford Textbook of Orthopaedics and Trauma. C. Bulstrode, et al. Editors. Oxford University Press, 2002.
9. Papagelopoulos PJ, Galanis E, McDonald D, Sim FH. Malignant fibrous histiocytoma of bone. Chapter, 288-94n: Oxford Textbook of Orthopaedics and Trauma. C. Bulstrode, et al., Editors. Oxford University Press, 2002.
10. Papagelopoulos PJ, Galanis E, Ruggieri P, Sim FH. Osteblastoma. Chapter, 157-161 in: Oxford Textbook of Orthopaedics and Trauma. C. Bulstrode, et al., Editors. Oxford University Press, 2002.
11. Papagelopoulos PJ, Galanis E, Sim FH. Metastatic neoplasms: Metastatic bone disease due to carcinoma. Chapter, 340-58 in: Oxford Textbook of Orthopaedics and Trauma. C. Bulstrode, et al., Editors. Oxford University Press, 2002.
12. Papagelopoulos PJ, Galanis EC, Arndt CAS, Sim FH. Metastatic neuroblastoma. In: Bulstrode C, et al, editors. Oxford textbook of orthopedics and trauma. Volume 1. Oxford: Oxford University Press; 2002. p. 358-61.
13. Papagelopoulos PJ, Galanis EC, Arndt CAS, Sim FH. Wilms' tumor. In: Bulstrode C, et al, editors. Oxford textbook of orthopedics and trauma. Volume 1. Oxford: Oxford University Press; 2002. p. 361-3.
14. Papagelopoulos PJ, Galanis EC, McDonald DJ, Sim FH. Fibrosarcoma of bone. In: Bulstrode C, et al, editors. Oxford textbook of orthopedics and trauma. Volume 1. Oxford: Oxford University Press; 2002. p. 283-8.
15. Papagelopoulos PJ, Galanis EC, McDonald DJ, Sim FH. Malignant fibrous histiocytoma of bone. In: Bulstrode C, et al, editors. Oxford textbook of orthopedics and trauma. Volume 1. Oxford: Oxford University Press; 2002. p. 288-94.
16. Papagelopoulos PJ, Galanis EC, Ruggieri P, Sim FH. Osteblastoma. In: Bulstrode C, et al, editors. Oxford textbook of orthopedics and trauma. Volume 1. Oxford: Oxford University Press; 2002. p. 157-61.
17. Papagelopoulos PJ, Galanis EC, Sim FH. Metastatic bone disease due to carcinoma. In: Bulstrode C, et al, editors. Oxford textbook of orthopedics and trauma. Volume 1. Oxford: Oxford University Press; 2002. p. 340-58.
18. Papagelopoulos PJ, Turcotte RE, Galanis EC, Wold LE, Sim FH. Primary cystic and neoplastic diseases of bone. In: Coe FL, Favus MJ, editors. Disorders of bone and mineral metabolism. 2nd Edition. Philadelphia: Lippincott Williams & Wilkins; 2002. p. 1021-50.
19. Galanis E, Buckner JC. Diffuse cerebral gliomas in adults. In: Noseworthy JH, editor. Neurological therapeutics : principles and practice. Volume 1. London: Martin Dunitz; 2003. p. 737-53.
20. Springfield C, Fielding A, Peng KW, Galanis E, Russell SJ, Cattaneo R. Measles virus: improving natural oncolytic properties by genetic engineering. In: Sinkovics JG, Horvath JC, editors. Viral therapy of human cancers. New York: Marcel Dekker; 2005. p. 459-80.

21. Galanis E, Buckner JC. Diffuse cerebral gliomas in adults. In: Noseworthy JH, editor. Neurological therapeutics: principles and practice. 2nd Edition. Volume 1. Abingdon: Informa Healthcare; 2006. p. 832-53.
22. Galanis E. Cancer gene therapy clinical trials: from the bench to the clinic. In: Adjei AA, Buolamwini JK. Novel Anticancer Agents: Strategies for Discovery and Clinical Testing. New York: Elsevier (Academic Press); 2006. p. 379-90.
23. Rao RD, Brown PD, Giannini C, Maher CO, Meyer FB, Galanis E, Erickson BJ, Buckner JC. Central nervous system tumors. In: Chang AE, et al, editors. Oncology: an evidence-based approach. New York: Springer; 2006. p. 487-505.
24. Galanis E. Malignant central nervous system neoplasms of mesenchymal origin. In: Baehring JM, Piepmeyer JM, editors. Brain tumors: practical guide to diagnosis and treatment. Vol. 89. New York: Informa Healthcare; 2007. p. 325-40.

### Editorials

1. Peng KW, Galanis E. Sindbis vectors: illuminating the path to ovarian cancer therapy. Gene Ther 2005 Mar; 12(5):381-2.

### Abstracts and Letters

1. Galanis E, Lymperi P, Manesis E, Harrison J, Murtaugh P, Hadgiyannis S. Specificity and titer of MS-AMA in patients with chronic liver disease. Hepatology 1992; 16(4 pt 2):190A.
2. Galanis E, Balan V, Wiesner RH, Batts KP, Hay JE, Gores GJ, Porayko MK, Steers JL, Dickson ER, Krom RAF, Gershwin E, Homburger HA. Presence of IgG3 isotype of M2 antimitochondrial antibody suggests recurrent of primary biliary cirrhosis (PCB) after orthotopic liver transplantation (OLT). (Abstract no. 10). Hepatology 1993 Oct; 18:59A.
3. Papagelopoulos P, Galanis E, Hay JE, Morrey B. Total joint replacement in orthotopic liver transplant recipients. Orthopaedic Transactions 1995; 19(3):778.
4. Papagelopoulos PJ, Galanis EC, Currier BL. Aneurysmal bone cysts of spine. (Abstract no. 84). J Bone Joint Surg Br 1995; 77-B(Suppl II):157.
5. Rubin J, Charboneau JW, Reading CC, Galanis E, Pitot H, Kovach JS. Phase I study of immunotherapy of hepatic metastasis of colorectal carcinoma by direct gene transfer. (Abstract no. 589). Program/Proc Am Soc Clin Oncol 1995 Mar; 14:228.
6. Galanis E, Frytak S, Lloyd R. Extrapulmonary small cell carcinoma: epidemiology and response to treatment. Journal of Investigative Medicine 1996; 44(3):249A.
7. Papagelopoulos PJ, Galanis E, Idosuyi OB, Greipp P, Sim FH. Prosthetic hip replacement for treatment of pathologic or impending pathologic fractures in multiple myeloma. (Abstract). Orthop Trans J Bone Joint Surg - Am. 20:36, 1996.
8. Papagelopoulos PJ, Galanis EC, Sim FH. Prosthetic hip replacement for treatment of pathologic or impending pathologic fractures in multiple myeloma. J Bone Joint Surg 1996; 78-B(Suppl II & III):151.

9. Vogelzang NJ, Sudakoff G, Hersh EM, Stopeck A, Rubin J, Galanis E, Schreiber A, Stahl S. Clinical experience in phase I and phase II testing of direct intratumoral administration with alovectin-7: a gene-based immunotherapeutic agent. Proc Annu Meet Am Soc Clin Oncol 1996; 15:235.
10. Galanis E, Buckner JC, Hammack J, Raffel C. Chemotherapy for advanced medulloblastoma and other central nervous system embryonal tumors in adults. (Abstract P02.042). Neurology 1996 Feb; 46(Suppl):A181.
11. Galanis E, Buckner J, Hammack J, Schomberg P, Raffel C. Chemotherapy (CT) for advanced medulloblastoma and other CNS embryonal tumors in adults. (Abstract no. 284). Program/Proc Am Soc Clin Oncol 1996 Mar; 15:155.
12. Galanis E, Frytak S, Lloyd R. Extrapulmonary small cell carcinoma. (Abstract no. 1421). Program/Proc Am Soc Clin Oncol 1996 Mar; 15:454.
13. Galanis E, Frytak S, Rowland KM, Lennon VA. Prevalence and titers of paraneoplastic anti-neuronal autoantibodies in the course of small cell lung carcinoma and platinum associated neuropathy. (Abstract no. 1212). Program/Proc Am Soc Clin Oncol 1996 Mar; 15:399.
14. Gelczer RK, Charboneau JW, Reading CC, Rubin J, Galanis E, Stahl SM. Imaging-guided immunotherapy of hepatic metastases from colorectal carcinoma. (Abstract 1449). Radiology 1996 Nov; 201(P Suppl):396.
15. Galanis E, Buckner J, Dinapoli R, Schomberg P, Jenkins R, Schaefer P, Wang C, O'Fallon J. Gliosarcoma (GS): a glioblastoma multiforme (GBM) variant? Proc Annu Meet Am Assoc Cancer Res 1997; 38:536.
16. Galanis E, Buckner J, Kimmel D, Schomberg P, Piepgras D. Management of recurrent meningeal hemangiopericytoma. (Abstract 1402). Program/Proc Am Soc Clin Oncol 1997; 16:393a.
17. Galanis E, Edmonson JH, Papagelopoulos PJ, Nascimento AG. Chemotherapy for advanced epithelioid sarcoma. (Abstract 1817). Program/Proc Am Soc Clin Oncol 1997; 16:505a.
18. Papagelopoulos P, Carci-LLuch B, Galanis E. Malignant tumors of the proximal end of the fibula. A clinicopathological study of 93 patients. (Abstract O 017). J Bone Joint Surg 1997; 79-B(Suppl 2):154.
19. Papagelopoulos PJ, Carci-LLuch B, Galanis E, Sim F, Unni KK. Benign tumors of the proximal end of the fibula. A clinicopathological study of 96 patients. (Abstract). Orthop Trans J Bone Joint Surg - Am. 21:45, 1997.
20. Papagelopoulos PJ, Carci-LLuch B, Galanis E, Sim FH, Unni KK. Malignant tumors of the proximal fibula. A clinicopathological study of 93 patients. (Abstract). Orthop Trans J Bone Joint Surg - Am. 21:46, 1997.
21. Rubin J, Galanis E, Burch P, Hersh EM, Spier C, Akporiaye E, Gonzalez R, Rinehart JJ, Sobol RE, Sondak VK, Stahl SM. Phase I/II trial of the IL-2 DNA/DMRIE/dope lipid complex as an immunotherapeutic agent by direct gene transfer in patients with advanced melanoma, renal cell carcinoma, and sarcoma. Cancer Gene Ther 1997; 4(6):S49.
22. Galanis E, Li CY, Phyliky R. Mast cell disease mimicking granulocytic sarcoma. Am J Hematol 1997 Nov; 56(3):194-5.

23. Galanis E, Buckner J, Novotny P, Dinapoli R, Schomberg P, Morton R, McGinnis W, O'Fallon J. Utility of neuroimaging, neurologic examination and symptom status in follow-up of high-grade glioma patients. (Abstract 1465). Program/Proceedings of the American Society of Clinical Oncology 1998; 17:380a.
24. Galanis E, Goldberg RM, Erlichman C, Rubin J, Pitot HC, Adjei AA, Alberts SR, Burch PA, Reid JM, Safgren SL, Witzig TE, Sloan JA, Ames MM. Phase I trial of sequential administration of Tomudex and 5-iodo-2'-deoxyuridine (IdUrd). Proc Annu Meet Am Assoc Cancer Res 1998; 39:321.
25. Galanis E, Rubin J, Burch P, Hersh EM, Spier C, Akporiaye E, Gonzalez R, Rinehart JJ, Sobol RE, Rorscher C, Sondak VK, Selk L. Phase I/II trial of immunotherapy by direct gene transfer of the IL-2 DNA/DMRIE/Dope lipid complex in patients with metastatic melanoma, renal cell carcinoma, and sarcoma. (Abstract). Gene Therapy and Molecular Biology. 2:373,1998.
26. Papagelopoulos P, Galanis E, Frassica F, Sim F. Primary fibrosarcoma of the bone: a clinicopathologic study of 129 patients. Journal of Bone and Joint Surgery Volume 1998; 80-B(Suppl 1):86.
27. Papagelopoulos P, Galanis E, Sim F, Unni K. Malignant tumors of the proximal end of the fibula. A clinicopathological study of 94 patients. Journal of Bone and Joint Surgery Volume 1998; 80-B(Suppl 1):86-7.
28. Rubin J, Galanis E, Burch P, Hersh E, Spier C, Akporiaye E, Gonzalez R, Rinehart J, Sobol R, Kimmel S, Sondak V, Selk L. Phase I/II trial of immunotherapy by direct gene transfer of the IL-2 DNA/dmrie/dope lipid complex in patients with advanced melanoma renal cell carcinoma, and sarcoma. (Abstract 1656). Program/Proceedings of the American Society of Clinical Oncology 1998; 17:430a.
29. Papagelopoulos PJ, Hay JE, Galanis E, Morrey BF. Infection around joint replacements in patients who have a renal or liver transplantation. J Bone Joint Surg Am 1998 Apr; 80(4):607-8.
30. Rubin J, Galanis E, Pitot HC, Burch PA, Akporiaye ET, Harris DT. Immunotherapy of metastatic disease by direct gene transfer of the HLA-B7//beta 2 microglobulin genes.(Abstract). Gene Therapy and Molecular Biology. 2:371,1998 Aug.
31. Erlichman C, Adjei A, Sloan J, Pitot H, Goldberg R, Peethambaram P, Alberts S, Galanis E, Hanson L, Reid J, Rubin J, Burch P, Thornton D, Walling J. A Phase I trial of MTA (multi-targeted antifolate, LY231514) and gemcitabine (Gemzar) in patients with locally advanced or metastatic cancer. (Abstract 658). Program/Proc Am Soc Clin Oncol 1999; 18:172a.
32. Figlin R, Galanis E, Thompson J, Gillespie D. Direct gene transfer of a plasmid encoding the IL-2 gene (Leuvectin) as treatment for patients with metastatic renal cell carcinomas (RCC). (Abstract). Proc ASCO. 18:431a, 1999.
33. Galanis E, Goldberg R, Erlichman C, Sloan J, Reid J, Pitot H, Rubin J, Alberts S, Adjei A, Burch P, Safgren S, Atherton-Skaff P, Witzig T, Ames M. Phase I trial of sequential administration of Tomudex and 5-Iodo-2'-Deoxyuridine (IdUrd). (Abstract 660). Program/Proc Am Soc Clin Oncol 1999; 18:172a.
34. Papagelopoulos P, Galanis E, Frassica F, Sim F, Unni K. Distal fibulectomy for malignant or aggressive benign tumors. (Abstract O 257). J Bone Joint Surg 1999; 81-B(Suppl II):192.

35. Reid, T, Rubin, J, Galanis E, Abbruzzese, Lowe A, Sze D, Romel L, Kirn D. Hepatic artery infusion of onyx-015 in combination with 5-FU/leukovorin for metastatic gastrointestinal cancer metastatic to the liver: A phase I/II study. (Abstract). *Clinical Cancer Research*. (5) 3798S, 1999.
36. Galanis E, Goldberg R, Erlichman C, Sloan J, Reid J, Pitot H, Safgren S, Atherton-Skaff P, Witzig T, Ames M. Phase I trial of sequential administration of Tomudex and 5-iodo-2'-deoxyuridine (IdUrd). *Eur J Cancer* 1999 Sep; 35(Suppl 4):S286.
37. Galanis E, Vile R, James CD, Russell SJ. Use of measles virus F and H fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. (Abstract 151-O). *Neuro-oncol* 1999 Oct; 1(Abstract iss. 2):S106.
38. Galanis E, Vile R, James CD, Russell SJ. Fusogenic membrane glycoproteins as therapeutic transgenes in gliomas. (Abstract 77). *Neuro-oncol* 1999 Oct; 1(4):312.
39. Thomas CY, Stallings-Mann M, Galanis E, Wharen R. Evidence that loss of the PTEN/MMAC1 tumor suppressor gene cooperates with other glioblastoma-related mutations to constitutively activate growth factor signal transduction pathways and deregulate the cell cycle. (Abstract 195). *Neuro-oncol* 1999 Oct; 1(4):341-342.
40. Reid T, Rubin J, Galanis E, Abbruzzese J, Lowe A, Sze D, Romel L, Kim D. Hepatic artery infusion of ONYX-015 in combination with 5-FU/leucovorin for metastatic gastrointestinal cancer metastatic to the liver: A phase I/II study. (Abstract 341). *Proc AACR*. 5:3798s, 1999 Nov.
41. Galanis E, Buckner JC, Novotny P, Morton RF, McGinnis WL, Dinapoli RP, Schomberg P, O'Fallon JR. Utility of neuroimaging, neurologic examination, and symptom status in follow-up of high-grade gliomapatients. (Abstract) *J Neurosurg*. 93:201-7, 2000.
42. Galanis E, Johnson K, Vile R, Diaz RM, James CD, Russell S. Use of fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. (Abstract). *Molecular Therapy*. 1:S150, 2000.
43. Hidalgo M, Rowinsky E, Erlichman C, Drengler R, Marshall B, Adjei A, Hammond L, Speicher L, Galanis E, Edwards T, Boni J, Dukart G, Buckner J, Tolcher A. CCI-779, a rapamycin analog and multifaceted inhibitor of signal transduction: a phase I study. (Abstract 726). *Program/Proc Am Soc Clin Oncol* 2000; 19:187a.
44. Okuno SH, Edmonson JH, Mahoney MR, Buckner JC, Frytak S, Galanis E. Limited activity and acceptable toxicity of gemcitabine in a phase II study of patients (pts) with advanced sarcomas: a Mayo cancer center study. (Abstract 2188). *Program/Proc Am Soc Clin Oncol* 2000; 19:555a.
45. Reid T, Galanis E, Abbruzzese J, Sze D, Romel L, Hatfield M, Rubin J, Kirn D. Hepatic artery infusion of Onyx-015, a selectively replicating adenovirus, in combination with 5-FU/leucovorin for gastrointestinal carcinoma metastatic to the liver: a phase I/II trial. (Abstract 953). *Program/Proc Am Soc Clin Oncol* 2000; 19:246a.
46. Russell SJ, Galanis E, Vile R, Johnson K, James CD. Use of fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. *Proc Annu Meet Am Assoc Cancer Res* 2000 Mar; (41):259.
47. Hidalgo M, Rowinsky E, Erlichman C, Drengler R, Marshall B, Adjei A, Hammond L, Galanis E, Edwards T, Boni J, Tolcher A, Dukart G, Buckner J. A phase I and pharmacological study of CCI-779, a rapamycin analog cell cycle inhibitor. (Abstract). *European Society for Clinical Oncology* 2000 Oct.



48. Hidalgo M, Rowinsky E, Erlichman C, Drengler R, Marshall B, Adjei A, Hammond L, Galanis E, Edwards T, Burton J, Boni J, Tolcher A, Dukart G, Buckner J. Phase I and pharmacological study of CCI-779, a cell cycle inhibitor. *Clin Cancer Res* 2000 Nov; 6(11 Suppl):4548-9s.
49. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews J, Randlev B, Romel L, Rubin J, Kim D. Phase I/II study of intra-arterial administration of a replication-selective adenovirus CI-1042 (Onyx-015) in patients with metastatic colorectal carcinoma. (Abstract 519). *Clin Cancer Res* 2000 Nov; 6(Suppl):4570s.
50. Thompson JA, Figlin R, Galanis E, Bukowski R, Gutheil J. Phase II trial of plasmid DNA/lipid (Leuvectin) immunotherapy in patients with metastatic renal cell carcinoma. (Abstract 517). *Clin Cancer Res* 2000 Nov; 6(Suppl):4569s-4570s.
51. Galanis E, Bateman A, Johnson K, Diaz RM, James CD, Vile R, Russell SJ. Measles virus (MV-F and MV-H) and Gibbon ape leukemia virus (GALV.fus) deriving fusogenic membrane glycoproteins are potent transgenes in the gene therapy of gliomas. (Abstract). *Molecular Therapy*. 3:S114, 2001.
52. Galanis E, Bateman AR, Johnson KJ, Diaz RM, James CD, Vile RG, Russell SJ. Use of viral fusogenic membrane glycoproteins (fmg) as novel therapeutic transgenes in gliomas. (Abstract 214). *Program/Proc Am Soc Clin Oncol* 2001; 20(1 of 2):54a.
53. Gornet MK, Galanis E, Frytak S, McElroy E. Merkel cell carcinoma: The Mayo Clinic experience. (Abstract). *Proc ASCO*. 20:64a, 2001.
54. Johnson K, Peng K-W, Russell SJ, Galanis E. Metalloproteinase cleavable linkers can target the cytotoxicity of fusogenic membrane glycoproteins in gliomas. (Abstract). *Molecular Therapy*. 3:S25, 2001.
55. Papagelopoulos PJ, Galanis E, Triantafyllidis P, Bond JR, Unni KK, Sim FH. Periosteal chondrosarcoma. A clinicopathological study of 24 patients. *EFFORT European Orthop Association Meeting*. Rhodes, Greece.
56. Reid T, Galanis E, Abbruzzese J, Sze D, Andrews JC, Randlev B, Rubin J, Kim D. Intra-arterial administration of a replication-selective adenovirus CI-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biologic activity. *ASCO Proceedings* 2001; 20:138a.
57. Reid TR, Galanis E, Abbruzzese J, Sze D, Andrews J, Randlev B, Rubin J, Kim D. Intra-arterial administration of a replication-selective adenovirus CI-1042 (Onyx-015) in patients with colorectal carcinoma metastatic to the liver: Safety, feasibility and biological activity. (Abstract). *Cancer Gene Therapy*. 8(Suppl 2):S10, 2001.
58. Buckner J, Jaeckle K, Galanis E, Uhm J, O'Neill B, Moynihan T, Brown P, Sarkaria J, Schomberg P, Erickson B, Schaefer P, Flynn P, Reid J, Jenkins R, James C, Scheithauer BW, Giannini C, O'Fallon JR. North Central Cancer Treatment Group (NCCTG) Neuro-Oncology Program. (Abstract). 14th International Conference on Brain Tumor Research and Therapy. Asheville, NC. 2001 May.
59. Buckner J, Jaeckle K, Galanis E, Uhm J, O'Neill B, Moynihan T, Brown P, Sarkaria J, Schomberg P, Erickson B, Schaefer P, Flynn P, Reid J, Jenkins R, James C, Scheithauer BW, Giannini C, O'Fallon JR. North Central Cancer Treatment Group (NCCTG) neuro-oncology program. (Abstract 22). *Neuro-oncol* 2001 Oct; 3(Suppl 1):S6-7.

60. TenEyck C, Galanis E, Kalli K, Hartmann L, Russell SJ, Peng KW. A trackable vaccine strain of measles virus for intraperitoneal therapy of ovarian cancer. *Gene Ther* 2001 Oct; 8(Suppl. 1):S12.
61. Galanis E, Okuno S, Lewis BS, Oliveira A, Nascimento AG, Sloan JA, Edmonson JH, Randlev B, Uprichard M, Rubin J. Phase I/II trial of ONYX-015 in combination with chemotherapy in patients with advanced sarcomas. (Abstract 646). *Clin Cancer Res* 2001 Nov; 7(Suppl):3783s.
62. Peng KW, TenEyck CJ, Galanis E, Kalli KR, Hartmann LC, Russell SJ. Intraperitoneal therapy of ovarian cancer using an engineered measles virus. (Abstract). *Molecular Therapy*. 5(5):S444, 2002.
63. Phuong LK, Peng KW, Allen C, Giannini C, TenEyck CJ, Russell SJ, Galanis E. Use of a vaccine strain of measles virus genetically engineered to produce CEA as a novel therapeutic agent against glioblastoma multiforme. (Abstract). *Molecular Therapy* 2002; 5(5):S302.
64. Reid TR, Galanis E, Sze D, Rubin J, Abbruzzese JL, Kirn D, Freeman S. Intra-arterial administration of a replication-selective adenovirus ONYX-015 in patients with colorectal carcinoma metastatic to the liver: safety, feasibility and biological activity (Abstract 535). *Program/Proc Am Soc Clin Oncol* 2002; 21(1):134a.
65. Richards J, Thompson J, Atkins MB, Hutchins L, Schuchter L, Gutheil J, Galanis E. A controlled, randomized phase III trial comparing the response to dacarbazine with and without Allovectin-7 (A) in patients with metastatic melanoma (Abstract 1380). *Program/Proc Am Soc Clin Oncol* 2002; 21(1):346a.
66. Galanis E, Okuno SH, Lewis BD, Oliveira AM, Nascimento A, Sloan JA, Edmonson JH, Randlev B, Freeman S, Rubin J. Phase I/II trial of ONYX-015 in combination with MAP chemotherapy in patients with advanced sarcomas. *Proc Am Assoc Cancer Res Annu Meet* 2002 Mar; 43:588.
67. Phuong LK, Petell C, Peng KW, Russell S, Galanis E. Use of a vaccine strain of measles virus genetically engineered to produce CEA as a novel therapeutic agent against glioblastoma multiforme. *J Investig Med* 2002 Mar; 50(2):176A.
68. Phuong LK, Allen C, Peng KW, Giannini C, TenEyck CJ, Russell S, Galanis E. Use of a vaccine strain of measles virus genetically engineered to produce CEA as a novel therapeutic agent against glioblastoma multiforme (Abstract 324). *Neuro-oncol* 2002 Sep; 4(Suppl 1):S76.
69. Allen C, McDonald C, Peng KW, Rosales G, Russell SJ, Galanis E. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas through protease-substrate interaction. *Mol Ther* 2003; 8(5 pt 2):441a.
70. Bedikian AY, Gonzalez R, Richards J, Atkins MB, Whitman E, Morse MA, Amatruda T, Hutchins L, Thompson J, Galanis E. A phase II study of high-dose allovectin-7 patients with advanced metastatic melanoma. *Proc Am Soc Clin Oncol* 2003; 22:2897a.
71. Galanis E, Maurer MJ, Ballman KV, O'Fallon JR, Sykora R, Castillo R, Buckner JC, Erickson BJ. Validation of neuroradiologic response assessment in gliomas: RECIST (1D) vs 2D measurements vs computer-assisted tumor area vs volume. (Abstract 423). *Proc Am Soc Clin Oncol*. 22:106, 2003.
72. Myers R, Frenzke M, Greiner S, Harvey M, Soeffker D, Galanis E, Peng KW, Russell S. Toxicology of oncolytic measles after intraperitoneal administration in measles-susceptible mice. *Mol Ther* 2003; 8(5 pt 2):342a.

73. Peng KW, Soeffker D, Myers R, Frenzke M, Harvey M, Greiner S, Cattaneo R, Galanis E, Federspiel M, Russell S. Biodistribution of oncolytic recombinant Edmonston B measles virus in measles-susceptible mice. *Mol Ther* 2003; 7(5 pt 2):326a.
74. Reid TR, Sze D, Galanis E, Abbruzzese JL, Kirn S, Freeman S. Intra-arterial administration of a replication-selective adenovirus ONYX-015 in patients with colorectal carcinoma metastatic to the liver: safety, feasibility and biologic activity. *Proc Am Soc Clin Oncol* 2003; 22:793a.
75. Peng KW, Myers R, Frenke M, Greiner S, Harvey M, Soeffker D, Galanis E, Federspiel M, Russell SJ. Oncolytic measles virotherapy for ovarian cancer. *Cancer Gene Ther* 2004; 11(12):846.
76. Galanis E, Buckner JC, Maurer M, Ballman K, Hidalgo M, Kreisberg JI, Boni J, James CDD, Jenkins RB, Walsh DJ. NCCTG phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM) (Abstract 1503). *Program/Proceedings of the American Society of Clinical Oncology* 2004 Jul 15; 22(14S):107s.
77. Richards J, Bedikian AY, Gonzalez R, Atkins MB, Whitman ED, Lutzky J, Morse MA, Amatruda T, Galanis E. A phase 2 trial of high-dose allovectin-7 in patients with advanced metastatic melanoma (Abstract 7509). *Program/Proceedings of the American Society of Clinical Oncology* 2004 Jul 15; 22(14S):721s.
78. Allen C, Vongpunsawa S, Nakamura T, James CD, Schroeder M, Cattaneo R, Russell SJ, Galanis E. EGFRvIII retargeted oncolytic measles virus strains have significant antitumor activity against gliomas. (Abstract 720). *Mol Ther* 2005; 11(1):s279.
79. Galanis E, Buckner JC, Maurer MJ, Hidalgo M, Kreisberg JI, Peralba J, Jenkins RB, Walsh DJ. N997B: phase II trial of CCI-779 in recurrent glioblastoma multiforme (GBM): updated results and correlative laboratory analysis (Abstract 1505). *J Clin Oncol* 2005 Jun; 23(16S part I):115s.
80. Gill P, Galanis E, Buckner J, Christianson T, Anderson P, Ansell S, Litzow M. High dose chemotherapy (HDC) with autologous stem cell transplantation (ASCT) in adults with relapsed CNS embryonal tumors (Abstract 1525). *J Clin Oncol* 2005 Jun; 23(16S part I):120s.
81. Richards JM, Bedikian A, Gonzalez R, Atkins MB, Whitman E, Lutzky J, Morse MA, Amatruda T, Galanis E, Thompson J. High-dose Allovectin-7 in patients with advanced metastatic melanoma: final phase 2 data and design of phase 3 registration trial (Abstract 7543). *J Clin Oncol* 2005 Jun; 23(16S part I):720s.
82. Allen C, Vongpunsawad S, Nakamura T, James CD, Schroeder M, Cattaneo R, Giannini C, Krempski J, Russell SJ, Galanis E. EGFRvIII retargeted oncolytic measles virus strains have significant antitumor activity against gliomas. (Abstract 430). *Mol Ther* 2006; 13(Suppl 1):S165-6.
83. Galanis E, Hartmann LC, Cliby WA, Zollman P, Peethambaram PP, Long HJ, Kaur JS, Sloan JA, Poland GA, Peng KW, Russell SJ. Phase I trial of intraperitoneal (IP) administration of measles virus (MV) strain expressing the human carcinoembryonic antigen (CEA) in ovarian cancer patients. (Abstract 729). *Mol Ther* 2006; 13(Suppl 1):S281.
84. Liu C, Sarkaria JN, Allen C, Zollman PJ, James CD, Russell SJ, Galanis E. Combination of oncolytic measles virus strains and radiation therapy has synergistic activity in the treatment of glioblastoma multiforme. (Abstract 44). *Mol Ther* 2006; 13(Suppl 1):S19.

85. Myers, Harvey ME, Greiner SM, Soeffker DC, Krempski JW, Zollman PJ, Shelton SE, Raffel C, Goerss SJ, Kaufman TJ, Federspiel MJ, Peng KW, Russell SJ, Galanis E. Safety of repeat intracerebral administration of MV-CEA in Rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas. (Abstract 297). *Mol Ther* 2006; 13(Suppl 1):S113.
86. Ballman KV, Jaeckle KA, Schomberg P, Giannini C, Galanis E, Brown P, Arusell R, Reid J, Hammack J, Buckner J. Phase II trial of irinotecan (CPT-11) and radiation followed by irinotecan and BCNU in glioblastoma patients (pts) (Abstract 1562). *J Clin Oncol* 2006 Jun; 24(18S):73s.
87. Buckner JC, Ballman K, Schaefer P, Furth AF, Giannini C, Scheithauer BW, Galanis E, Jaeckle KA. NCCTG 96-94-53: clinical variables associated with overall survival (OS), progression-free survival (PFS), 6 month progression-free survival (PFS6), immediate progression (ImmProg), and response in patients enrolled in recurrent glioma clinical trials (Abstract 1520). *J Clin Oncol* 2006 Jun; 24(18S):63s.
88. Galanis E, Hartmann LC, Cliby W, Zollman PJ, Peethambaram PP, Long HJ, Kaur JS, Sloan JA, Peng KW, Russell SJ. Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in ovarian cancer patients (Abstract 5028). *J Clin Oncol* 2006 Jun; 24(18S):262s.
89. Jaeckle KA, Furth AF, Wu W, Ballman KV, Flynn PJ, Brown PD, Galanis E, Buckner JC. Comparison of outcome of patients with newly diagnosed and recurrent gliomas treated on North Central Cancer Treatment Group (NCCTG) phase II and III trials within the community as compared to an academic medical center (Abstract EP-05). *Neuro-oncol* 2006 Oct; 8(4):406-7.
90. Allen C, Paraskevakou G, Iankov I, Schroeder M, Puri RK, Russell SJ, Galanis E. IL13 displaying retargeted oncolytic measles virus (MV) strains have significant activity and improved therapeutic index against gliomas. (Abstract 51) *Mol Ther* 2007; 15((suppl 1)):s22.
91. Galanis E, Jaeckle KA, Maurer MJ, Reid JM, Ames MM, Giannini C, Hardwick JS, Moore DF, Zwiebel JA, Buckner JC. N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM). (Abstract 2004). *J Clin Oncol* 2007; 25(18S:pt 1):76s.
92. Liu C, Erlichman C, McDonald CJ, Ingle JN, Zollman P, Iankov I, Russell SJ, Galanis E. Heat shock protein inhibitors increase the efficacy of measles virotherapy. (Abstract 47) *Mol Ther* 2007; 15(suppl 1):S20.
93. Ahrens WA, Hui P, Galanis E, Oliveira AM. Gastric spindle cell sarcomas may not gastrointestinal stromal tumors: Report of three cases of primary gastric synovial sarcoma with molecular confirmation. *Mod Pathol* 2007 Mar; 20(Suppl 2):106A.
94. Ahrens WA, Hui P, Galanis E, Oliveira AM. Gastric spindle cell sarcomas may not be gastrointestinal stromal tumors: Report of three cases of primary gastric synovial sarcoma with molecular confirmation. *Lab Invest* 2007 Mar; 87(Suppl 1):106A.
95. Raffel C, Galanis E, Giannini C, Kreofsky C, Russell S. Treatment of medulloblastoma with modified measles virus. *Neuro-oncol* 2007 Oct; 9(4):562.
96. Schiff D, Sarkaria J, Decker P, Buckner J, Galanis E, Dancey J, Giannini C, Brown P, Wiesenfeld M, Jaeckle K. Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572. *Neuro-oncol* 2007 Oct; 9(4):518.

97. Galanis E, Hartmann LC, Cliby W, Peethambaram P, Long HJ, Kaur JS, Haluska Jr P, Sloan JA, Peng KW, Russell SJ. Phase I trial of intraperitoneal (IP) administration of an oncolytic measles virus (MV) derivative, expressing the human carcinoembryonic antigen (CEA) in patients with advanced ovarian cancer (OvCa). (abstract 302). *Mol Ther* 2008; 16(suppl 1):s75.
98. Galanis E, Hartmann LC, Cliby W, Peethambaram PP, Long HJ, Kaur JS, Haluska Jr P, Sloan JA, Peng KW, Russell SJ. Phase I trial of intraperitoneal (IP) administration of a measles virus (MV) derivative expressing the human carcinoembryonic antigen (CEA) in recurrent ovarian cancer (OvCa). *J Clin Oncol* 2008; 26(15s, pt 1).
99. Galanis E, Jaeckle K, Buckner J, Maurer M, Hardwick J, Puduvalli V, Lamborn K, Kuhn J, Prados M, Wen PY. Vorinostat in glioblastoma multiforme (GBM): updated results from phase I and II trials provide the rationale for further clinical development. *ESMO Conference* 2008.
100. Iankov ID, Msaouel P, Allen C, Federspiel MJ, Ingle J, Russell SJ, Galanis E. Oncolytic measles virus strains are effective therapy for malignant pleural effusions in a xenograft model of advanced breast cancer. (abstract 736). *Mol Ther* 2008; 16(suppl 1):s275.
101. Msaouel P, Iankov ID, Allen C, Federspiel MJ, Morris JC, Koutsilieris M, Russell SJ, Galanis E. Oncolytic measles virus derivatives have significant antitumor activity against prostate cancer. (abstract 200). *Mol Ther* 2008; 16(suppl 1):s113.
102. Schiff D, Sarkaria J, Decker P, Buckner J, Galanis E, Dancey J, Giannini C, Brown P, Wiesenfeld M, Jaeckle K. Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572. 17th International Conference on Brain Tumor Research and Therapy (Accepted for Oral Presentation) 2008.